Health Care·Biotechnology·$6.4B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.44 | N/A | +375.00% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.44 | N/A | +375.00% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting their commitment to pipeline development. However, no specific guidance was provided for future performance.
We are pleased with our EPS performance this quarter.
Our focus remains on advancing our pipeline and enhancing shareholder value.
Protagonist Therapeutics reported a strong EPS performance, significantly exceeding expectations, which contributed to a slight increase in stock price. The lack of revenue data and guidance leaves some uncertainty, but the positive EPS surprise indicates potential strength in their operations. Investors may view this as a positive sign for the company's future prospects.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
WORKDAY INC A
Feb 26, 2024